PPCB 10-Q Quarterly Report March 31, 2014

PROPANC BIOPHARMA, INC.

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-K	Fiscal year ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-Q	Quarter ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-K	Fiscal year ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-Q	Quarter ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-K	Fiscal year ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-Q	Quarter ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-K	Fiscal year ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-Q	Quarter ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-K	Fiscal year ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-Q	Quarter ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-K	Fiscal year ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-Q	Quarter ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-K	Fiscal year ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-Q	Quarter ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-K	Fiscal year ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-Q	Quarter ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-K	Fiscal year ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-Q	Quarter ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-K	Fiscal year ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-Q	Quarter ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-K	Fiscal year ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-Q	Quarter ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-K	Fiscal year ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-Q	Quarter ended Dec. 31, 2013
10-Q	Quarter ended Nov. 13, 2013
10-K	Fiscal year ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-Q	Quarter ended Dec. 31, 2012
10-K	Fiscal year ended Oct. 11, 2012
10-Q	Quarter ended Sept. 30, 2012
10-Q	Quarter ended March 31, 2012
10-Q	Quarter ended Dec. 31, 2011

10-Q 1 ppch_10q.htm QUARTERLY REPORT ppch_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

þ	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2014

o	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number: 000-53446

PROPANC HEALTH GROUP CORPORATION

(Exact name of registrant as specified in its charter)

Delaware		33-0662986
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

Level 13, Suite 1307, 530 Collins Street

Melbourne, VIC, 3000 Australia

(Address of principal executive offices)

61 03 9614 2795

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer," "non-accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	þ
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ

State the number of shares outstanding of each of the issuer's classes of common equity, as of the latest practicable date. 72,684,768 shares of common stock as of May 19, 2014.

PROPANC HEALTH GROUP CORPORATION

Quarterly Report On Form 10-Q

For The Quarterly Period Ended

March 31, 2014

INDEX

		Page
PART I - FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements (unaudited)	3
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	16
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18
Item 4.	Controls and Procedures	18

PART II - OTHER INFORMATION
		19
Item 1.	Legal Proceedings	19
Item 1A.	Risk Factors	19
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	19
Item 3.	Defaults Upon Senior Securities	19
Item 4.	Mine Safety Disclosures	19
Item 5.	Other Information	19
Item 6.	Exhibits	19

PART I—FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

The following unaudited interim financial statements of Propanc Health Group Corporation (referred to herein as the "Company," "we," "us" or "our") are included in this quarterly report on Form 10-Q:

		Page

Consolidated Balance Sheets at March 31, 2014 (unaudited) and June 30, 2013		4

Consolidated Statements of Operations and Comprehensive loss for the three months and for the nine months ended March 31, 2014 and 2013 and for the period from October 15, 2007 (Inception) to March 31, 2014 (unaudited)		5

Consolidated Statements of Cash Flows for the nine months ended March 31, 2014 and 2013 and for the period from October 15, 2007 (Inception) to March 31, 2014 (unaudited)		6

Notes to the unaudited Consolidated Financial Statements (unaudited)		7

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED BALANCE SHEETS

	March 31, 2014			June 30, 2013
	unaudited
ASSETS

CURRENT ASSETS:
Cash	$	40		$	-
Prepaid expenses		-			-
GST tax receivable		-			1,209

TOTAL CURRENT ASSETS		40			1,209

Property and Equipment, net		-			538

TOTAL ASSETS	$	40		$	1,747

LIABILITIES AND STOCKHOLDERS' DEFICIT


CURRENT LIABILITIES:
Bank Overdraft	$	-		$	5
Accounts payable		332,287			272,596
Accrued expenses and other payables		373,286			251,439
Other Loans		35,608			32,879
Convertible Note, net of $107,881 debt discount		39,890			-
Warrant derivative liability		111,343			-
Due to directors - related parties		57,952			57,237
Loans from directors and officer - related parties		156,149			130,689
Employee benefit liability		58,719			49,378

TOTAL CURRENT LIABILITIES		1,165,234			794,223

Commitments and Contingencies (See Note 7)

STOCKHOLDERS' DEFICIT:
Preferred stock, $0.01 par value; 10,000,000 shares authorized; zero shares issued and outstanding as of March 31, 2014 and June 30, 2013, respectively		-			-
Common stock, $0.001 par value; 100,000,000 shares authorized; 72,684,768 and 70,632,267 shares issued and outstanding as of March 31, 2014 and June 30, 2013, respectively		72,686			70,632
Common stock issuable, $0.001 par value; 0 and 25,000 shares issued and outstanding as of March 31, 2014 and June 30, 2013, respectively		-			25
Additional Paid-in Capital		16,374,780			16,104,809
Accumulated other comprehensive loss		(277,330	)		(244,589	)
Deficit accumulated during development stage		(17,335,330	)		(16,723,353	)

TOTAL STOCKHOLDERS' DEFICIT		(1,165,194	)		(792,476	)

TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	40		$	1,747

The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2014 AND 2013

AND FOR THE PERIOD OCTOBER 15, 2007 (INCEPTION) TO MARCH 31, 2014

(UNAUDITED)

													For the period from
													October 15,
	For the Three Months Ended						For the Nine Months Ended						2007 (Inception)
	March 31,						March 31,						to March 31,
	2014			2013			2014			2013			2014
	unaudited			unaudited			unaudited			unaudited			unaudited
REVENUE
Royalty revenue - related party	$	-		$	-		$	-		$	-		$	30,974

OPERATING EXPENSES
Administration expenses		101,626			225,964			630,121			1,160,383			16,652,654
Occupancy expenses		2,689			3,403			8,217			10,000			77,871
Research and development		-			-			-			1,744			655,667
TOTAL OPERATING EXPENSES		104,315			229,367			638,338			1,172,127			17,386,192

LOSS FROM OPERATIONS		(104,315	)		(229,367	)		(638,338	)		(1,172,127	)		(17,355,218	)

OTHER INCOME (EXPENSE)
Interest expense		(19,901	)		(1,378	)		(42,291	)		(4,001	)		(221,919	)
Interest income		-			-			-			-			9,005
Change in fair value of warrant Derivative liability		58,650			-			27,016			-			27,016
Loss on Debt Settlements, net		-			(107,939	)		-			(107,939	)		(108,185	)
Foreign currency transaction gain (loss)		(1,299	)		982			(6,373	)		4,927			(53,449	)
TOTAL OTHER INCOME (EXPENSE)		37,450			(108,335	)		(21,648	)		(107,013	)		(347,532	)

LOSS BEFORE INCOME TAXES		(66,865	)		(337,702	)		(659,986	)		(1,279,140	)		(17,702,750	)

INCOME TAX BENEFIT		-			30			48,009			61,150			367,421

NET LOSS		(66,865	)		(337,672	)		(611,977	)		(1,217,990	)		(17,335,330	)

OTHER COMPREHENSIVE LOSS
Foreign currency translation loss		(47,909	)		(2,567	)		(32,741	)		(12,680	)		(277,330	)

COMPREHENSIVE LOSS	$	(114,774	)	$	(340,239	)	$	(644,718	)	$	(1,230,670	)	$	(17,612,660	)


BASIC AND DILUTED NET LOSS PER SHARE	$	(0.00	)	$	(0.00	)	$	(0.01	)	$	(0.02	)	$	(0.32	)

BASIC AND DILUTED WEIGHTED AVERAGE SHARES OUTSTANDING		72,684,768			72,298,309			72,234,522			72,938,995			54,913,729

The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.

PROPANC HEALTH GROUP CORORATION AND SUBSIDIARY

(A Development Stage Company)

CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED MARCH 31, 2014 AND 2013

AND FOR THE PERIOD OCTOBER 15, 2007 (INCEPTION) TO MARCH 31, 2014

(UNAUDITED)

							For the Period from
							October 15, 2007
	For the Nine Months Ended						(Inception)
	March 31,						to March 31,
	2014			2013			2014
	unaudited			unaudited			unaudited
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$	(611,977	)	$	(1,217,990	)	$	(17,335,330	)
Adjustments to Reconcile Net loss to Net Cash Used in Operating Activities:
Issuance of common stock for services and voluntary ratchet		237,833			797,283			1,716,563
Loss on settlement of debt		-			107,939			108,185
Consultant stock expense		-			-			48,000
Amortization of prepaid shares issued for services		6,667			37,917			11,189,926
Officer shares contributed to third party consultant		-			-			299,737
Write off of subscription receivable		-			-			325
Write off of previously capitalized patent costs		-			-			26,855
Foreign currency transaction (loss) gain		-			(4,927	)		43,256
Depreciation expense		538			978			14,749
Amortization of debt discount		30,434			-			30,434
Change in fair value of warrant derivative liability		(27,016	)		-			(27,016	)
Changes in Assets and Liabilities:
Escrow account		-			653			-
Accounts receivable		-			-			(664	)
GST receivable		-			-			798
Prepaid expenses and Other assets		1,224			2,804			3,799
Accounts payable		83,789			55,603			386,861
Employee benefit liability		8,725			8,731			59,374
Accrued expenses		122,728			113,457			445,537
Accrued interest		9,388			851			199,508

NET CASH USED IN OPERATING ACTIVITIES		(137,667	)		(96,701	)		(2,789,103	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment		-			-			(14,786	)
Patent costs		-			-			(25,726	)

NET CASH USED IN INVESTING ACTIVITIES		-			-			(40,512	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Bank Overdraft		(5	)		101			-
Sale of common stock		-			-			1,479,675
Contributed capital		-			-			495,665
Subscription receivable - related party		-			-			22
Related party expenses paid (and advances made) on behalf of company		67,760			-			125,022
Loan repayments to officer and directors		(45,511	)		(33,379	)		(93,205	)
Investor Advances - related party		-			-			79,112
Proceeds from convertible promissory note		103,959			-			246,265
Loan proceeds		10,542			37,362			48,048
Loan proceeds from related party		-			94,908			492,988

NET CASH PROVIDED BY FINANCING ACTIVITIES		136,745			98,992			2,873,592

Effect of exchange rate changes on cash		962			(2,470	)		(43,937	)

NET INCREASE (DECREASE) IN CASH		40			(179	)		40

CASH AT BEGINNING OF PERIOD		-			179			-

CASH AT END OF PERIOD	$	40		$	-		$	40

Supplemental Disclosure of Cash Flow Information

Cash paid during the period:
Interest	$	-		$	-		$	-
Income Tax	$	-		$	-		$	-
Supplemental Disclosure of Non-Cash Investing and Financing Activities

Conversion of notes payable to common stock	$	-		$	-		$	341,208
Conversion of accrued interest to common stock	$	-		$	1,896		$	195,544
Gain on related party debt conversion	$	-		$	-		$	9,252
Prepaid common stock issued for services	$	6,667		$	-		$	10,867,632
Advance from investor - related party, reclassified to common stock	$	-		$	-		$	80,000
Conversion of accrued expenses to common stock	$	27,500		$	37,500		$	101,272
Conversion of convertible notes and accrued interest to common stock	$	-		$	75,000		$	150,894
Conversion of loan payable to convertible debenture	$	27,963		$	-		$	27,963
Discounts related to warrants issued with convertible debenture	$	133,095		$	-		$	133,095

The accompanying unaudited notes are an integral part of these unaudited consolidated financial statements.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 1 – NATURE OF OPERATIONS, BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING AND REPORTING POLICIES

Nature of Operations:

Propanc Health Group Corporation, formerly Propanc PTY LTD, (referred to herein as the "Company," "we," "us" or "our") is a development stage enterprise. Propanc PTY LTD was incorporated in Melbourne, Victoria Australia on October 15, 2007, and is based in Richmond, Victoria Australia. Since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow-up, non-toxic, long-term therapy which prevents the cancer from returning and spreading. The Company is in the development stage and has begun raising capital, financial planning, establishing sources of supply, and acquiring property and equipment. The Company anticipates establishing global markets for its technologies.

On November 23, 2010, Propanc Health Group Corporation was incorporated in the state of Delaware. In January 2011, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc PTY LTD on a one-for-one basis making it a wholly-owned subsidiary. The results of operations through June 30, 2010 are that of the subsidiary, Propanc PTY LTD. All share and per share data in the accompanying unaudited consolidated financial statements has been retroactively adjusted for this recapitalization giving effect to a common share par value of $0.001.

Basis of Presentation:

The Company is presented as in the development stage from October 15, 2007 (Inception) through March 31, 2014.

The interim unaudited consolidated financial statements included herein have been prepared in accordance with accounting principles generally accepted in the United States of America, and pursuant to the rules and regulations of the Securities and Exchange Commission. In the opinion of the Company’s management, all adjustments (consisting of normal recurring adjustments and reclassifications and non-recurring adjustments) necessary to present fairly our results of operations and cash flows for the three and nine months ended March 31, 2014 and our financial position as of March 31, 2014 have been made. The results of operations for such interim periods are not necessarily indicative of the operating results to be expected for the full year.

Certain information and disclosures normally included in the notes to the annual audited consolidated financial statements have been condensed or omitted from these interim unaudited consolidated financial statements. Accordingly, these interim unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto for the fiscal year ended June 30, 2013. The June 30, 2013 balance sheet is derived from those statements.

Use of Estimates:

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates. Significant estimates in the accompanying unaudited consolidated financial statements include, without limitation, those involving depreciable lives and valuation of property and equipment and intangible assets, allowance for uncollectable receivables, valuation of derivatives, valuation of beneficial conversion features in convertible debt, valuation of equity based instruments issued for other than cash and the valuation allowance on deferred tax assets and foreign currency translation due to the application of certain average exchange rates in lieu of spot rates on translation dates.

Principals of Consolidation:

The unaudited consolidated financial statements include the accounts of Propanc Health Group Corporation and its wholly-owned subsidiary, Propanc PTY LTD. All significant inter-company balances and transactions have been eliminated in consolidation.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

Foreign Currency Translation and Comprehensive Income (Loss):

The Company’s functional currency is the Australian dollar (AUD). For financial reporting purposes, the Australian dollar has been translated into United States dollars ($) and/or USD as the reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Equity transactions are translated at each historical transaction date spot rate. Translation adjustments arising from the use of different exchange rates from period to period are included as a component of stockholders’ equity (deficit) as “accumulated other comprehensive income (loss).” Gains and losses resulting from foreign currency transactions are included in the statement of operations and comprehensive loss as other income (expense). There has been no significant fluctuations in the exchange rate for the conversion of Australian dollars to USD after the balance sheet date.

Comprehensive loss from inception, through March 31, 2014, included foreign currency translation gains (losses).

Changes in Accumulated Other Comprehensive Income (Loss) by Component during the nine months ended March 31, 2014 was as follows:

	Foreign Currency Items:
Beginning balance, June 30, 2013	$	(244,589	)
Other comprehensive income before reclassification		32,741
Amounts reclassified from accumulated other comprehensive income (loss)		-
Ending balance, March 31, 2014	$	(277,330	)

Derivative Instruments:

ASC Topic 815, Derivatives and Hedging (“ASC Topic 815”), establishes accounting and reporting standards for derivative instruments and for hedging activities by requiring that all derivatives be recognized in the balance sheet and measured at fair value. Gains or losses resulting from changes in the fair value of derivatives are recognized in earnings or recorded in other comprehensive income (loss) depending on the purpose of the derivatives and whether they qualify and have been designated for hedge accounting treatment. The Company does not have any derivative instruments for which it has applied hedge accounting treatment.

Fair Value of Financial Instruments and Fair Value Measurements:

We measure our financial assets and liabilities in accordance with United States generally accepted accounting principles. For certain of our financial instruments, including cash and cash equivalents, accounts and other receivables, accounts payable and accrued and other liabilities, the carrying amounts approximate fair value due to their short maturities. Amounts recorded for loans payable also approximate fair value because current interest rates available to us for debt with similar terms and maturities are substantially the same.

We adopted accounting guidance for fair value measurements of financial assets and liabilities. The adoption did not have a material impact on our consolidated results of operations, financial position or liquidity. This standard defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance does not apply to measurements related to share-based payments. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost). The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

Cash and Cash Equivalents:

Cash and cash equivalents include cash on hand and at banks, short-term deposits with an original maturity of three months or less held at call with financial institutions, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities on the balance sheets. There were no overdrafts or cash equivalents as of March 31, 2014.

Australian Goods and Services Tax (GST):

Revenues, expenses and balance sheet items are recognized net of the amount of GST except payable and receivable balances which are shown inclusive of GST. The GST incurred is payable on revenues to, and recoverable on purchases from, the Australian Taxation Office.

Cash flows are presented in the statements of cash flow on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

As of March 31, 2014, the Company owed $870 to the Australian Taxation Office.

Research and Development Tax Credits:

The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the claim amount. Accordingly, the Company does not recognize the benefit of the claim amount until cash receipt since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income then the Company can receive the credit which reduces its income tax liability. If the Company has net losses then the Company may still receive a cash payment for the credit, however, the Company's net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt.

Since inception, the Company has applied for and received from the Australian Taxation Office a research and development tax credit in the cumulative amount of $367,421 which is reflected as an income tax benefit in the accompanying unaudited consolidated statement of operations and comprehensive loss.

Basic and Diluted Net Loss Per Common Share:

Basic net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding during the period. Diluted net loss per common share is computed by dividing the net loss by the weighted average number of common shares outstanding for the period and, if dilutive, potential common shares outstanding during the period. Potentially dilutive securities consist of the incremental common shares issuable upon exercise of common stock equivalents such as stock options and convertible debt instruments. Potentially dilutive securities are excluded from the computation if their effect is anti-dilutive. As a result, the basic and diluted per share amounts for all periods presented are identical. As of March 31, 2014, there were 3,000,000 warrants outstanding and convertible notes payable that are convertible into 2,001,146 common shares which are considered dilutive securities which were excluded from the computation.

Recently Issued Accounting Pronouncements:

Financial Accounting Standards Board, Accounting Standard Updates which are not effective until after March 31, 2014 are not expected to have a significant effect on the Company’s unaudited consolidated financial position or results of operations.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 2 – GOING CONCERN

The accompanying unaudited consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. For the nine months ended March 31, 2014, the Company was in the development stage, had no revenues and had a net loss of $611,977 and net cash used in operations of $137,667. Additionally, as of March 31, 2014, the Company had working capital deficit, stockholders' deficit and a deficit accumulated during development stage of $1,165,194, $1,165,194 and $17,335,330. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The unaudited consolidated financial statements do not include any adjustments to reflect the possible future effect on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of this uncertainty.

The Company is in the development stage at March 31, 2014 and has been since its October 15, 2007 inception. Successful completion of the Company’s development program and, ultimately, the attainment of profitable operations are dependent upon future events, including obtaining adequate financing to fulfill its development activities, acceptance of the Company's international patent application and achieving a level of sales adequate to support the Company’s cost structure. However, there can be no assurances that the Company will be able to secure additional equity investment or achieve an adequate sales level.

NOTE 3 – DUE TO DIRECTORS - RELATED PARTY

Due to directors - related party represents unsecured advances made by the directors for operating expenses on behalf of the Company, such as intellectual property and formation expenses. The expenses were paid for on behalf of the Company and are due upon demand. The Company is currently not being charged interest under these advances. The total amount owed to these directors at March 31, 2014 and June 30, 2013 is $57,952 and $57,237, respectively.

NOTE 4 – LOANS

Loans from Directors and Officer - Related Parties

Loans from Directors and Officer at March 31, 2014 and June 30, 2013 were $156,149 and $130,689, respectively. The loans bear interest at rates of prime + 2% (5.25% at March 31, 2014) and are all past their due date and in default. Included in the above loan amounts is accrued interest of $3,316 as of March 31, 2014.

During the nine months ended March 31, 2014, the officer of the Company advanced approximately $68,000 to pay corporate expenses and was repaid for current and prior advances approximately $46,000 during the same period. The balance due this officer at March 31, 2014 is included in the above $156,149.

Loans from Unrelated Parties

Loans from two unrelated parties were received during fiscal 2013 totaling $24,042. They bear interest at 10% and as of March 31, 2014 were past their due date and in default. Accrued interest was $838 at March 31, 2014.

Loans from two unrelated parties were received during the three months to March 31, 2014 totaling $10,542. They bear interest at 10%. Accrued interest was $186 at March 31, 2014.

A loan from an unrelated party with a September 30, 2013 balance of $27,963 was exchanged for a convertible debenture as discussed below in note 5.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 5 – CONVERTIBLE DEBENTURE

On September 30, 2013 the Company’s subsidiary issued a Debenture for $139,680 (AUD$150,000) plus warrants for 3,000,000 common shares of the Company. The Company agreed to pay 12% interest on the principal amount and the maturity date is December 31, 2015. This debenture rolls into it $27,963 of loans outstanding at June 30, 2013 (see Note 4), an August 2013 note of $63,196 along with September advances of $46,446 and accrued interest. The debenture is convertible only at the Company’s option into common stock at $0.0698 per share and is convertible at that same rate by the lender only upon default by the Company, as defined in the debenture. The warrants were determined to be derivative instruments due to the variable exercise price of the warrants which is initially $0.0698 and subject to adjustment if the Company issues shares at a price below the initial exercise price. Accordingly, the fair value of the warrants was determined using a Black-Scholes option pricing model with a stock price of $0.20, exercise price of $0.0698, volatility of 53% based on the comparative companies method since the Company’s stock is very thinly traded, an expected term of 27 months based on the debenture term and a risk free rate of 0.4%. The approximate initial $400,000 value of the warrants was recorded as a derivative liability in the accompany unaudited balance sheet, along with a debt discount of approximately $140,000 and change in warrant derivative liability of approximately $260,000 as an expense for the three months ended September 30, 2013. (See note 10 for current period re-measurement)

Principal amount of convertible debt				Unamortized discount				Accrued interest				Convertible notes payable, net of discount
$	138,705	*		$	(107,881	)		$	9,066			$	39,890

* This amount may very at each reporting period based on foreign currency exchange rate changes.

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 6 – STOCKHOLDERS’ EQUITY (DEFICIT)

Common stock:

In July 2013, the Company issued 300,000 shares of common stock to a consultant related to a June 6, 2013 agreement. The shares were valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $12,000 during the first quarter of fiscal 2014 and $48,000 was previously recognized during fiscal 2013 as the expense was amortized over the term of the agreement.

In July 2013, the Company issued 250,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $50,000 related to the share issuance.

In July 2013, the Company issued 137,500 shares of common stock to a consultant in exchange for a $27,500 accounts payable relating to past services. The shares are fully vested and valued at $0.20 per share (based on current market price) and accordingly there was no gain or loss on this settlement.

In July 2013, the Company issued 10,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $2,000 related to the share issuance.

In July 2013, the Company issued 150,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $30,000 related to the share issuance.

In September 2013, the Company issued the balance of 300,000 shares of common stock to a consultant related to a June 6, 2013 agreement. The shares were valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $60,000 during the three months ended September 30, 2013.

On September 30, 2013, pursuant to a consulting agreement, the company issued 25,000 shares of common stock for past services performed during the quarter. The shares were valued at $0.20 per share (based on current market price) and accordingly, the Company recognized an expense of $5,000 during the three months ended September 30, 2013.

In October 2013, the Company issued 500,000 vested shares of common stock as a non-refundable retainer in conjunction with a 90-day investment banking services agreement. The shares were valued at the market price on the day of the grant, $0.10, and the Company recorded an expense of $50,000.

In October 2013, the Company issued 200,000 shares of common stock to a consultant for services. The shares were issued to the consultant and vest over the three year term of the agreement. The shares were valued at $0.10 per share (based on current market price) and accordingly, the Company recognized an expense of $13,333 and has recorded $6,667 in prepaid expenses for January's services.

In October 2013, the Company issued 100,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.10 per share (based on current market price) and accordingly, the Company recognized an expense of $10,000 related to the share issuance.

In November 2013, the Company issued 30,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.10 per share (based on current market price) and accordingly, the Company recognized an expense of $3,000 related to the share issuance.

In November 2013, the Company issued 25,000 shares of common stock to a consultant for past services. The shares are fully vested and valued at $0.10 per share (based on current market price) and accordingly, the Company recognized an expense of $2,500 related to the share issuance.

Warrants:

During the three months ended September 30, 2013, pursuant to convertible debenture, the Company issued 3,000,000 warrants to purchase common stock. These warrants have an initial exercise price of $0.0698 per share which is subject to adjustment and expire 5 years from the date of issuance (See Note 5).

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 7 – COMMITMENTS AND CONTINGENCIES

Legal Matters:

From time to time, we may be involved in litigation relating to claims arising out of our operations in the normal course of business. As of March 31, 2014, there were no pending or threatened legal actions that could reasonably be expected to have a material adverse effect on the results of our operations.

Operating Agreements:

In November 2009, the Company entered into a commercialization agreement whereby the Company agreed to pay royalties of 2% of net revenues. Additionally, the Company agreed to pay 5% of each and every license agreement subscribed for. The contact is cancellable at any time by either party. To date, no amounts are owed under the agreement.

Operating Leases:

No formal agreement has been entered regarding leasing of office space but an accrued expense of $8,322 has been recognized for the period in anticipation of a month to month agreement retroactive to July 1, 2013 at $925 per month.

NOTE 8 – RELATED PARTY TRANSACTIONS

Since inception, Propanc Health Group Corporation has conducted transactions with directors and director related entities. These transactions included the following:

As of March 31, 2014, the Company owed the directors and an officer a total of $156,149, for money loaned to the Company throughout the years. (See Note 4)

As of March 31, 2014, the Company owed two directors a total of $57,952, respectively, for expenses incurred on behalf of the Company related to corporate startup costs and intellectual property (See Note 3).

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

NOTE 9 – CONCENTRATIONS AND RISKS

Concentration of Credit Risk:

The Company maintains its cash in bank and financial institution deposits in Australia. Bank deposits in Australian banks are uninsured. The Company has not experienced any losses in such accounts through March 31, 2014.

Product and Patent Concentration:

As of March 31, 2014 the Company was undertaking preclinical activities for their lead product. The Company was also undertaking research to uncover the mechanism of action of their lead product in order to screen new compounds for development.

The Company previously expanded by the filing of an international PCT patent application (No. PCT/AU2010/001403) directed to enhanced proenzyme formulations and combination therapies. The international PCT application has been based on previous provisional patent applications capturing the Company’s ongoing research and development in this area.

The Company recently completed the 30 month national phase filing deadline for this international patent and commenced entering the national phase in countries around the world. Provisional patents are currently being filed in the following countries/regions: United States, Japan, Brazil, China, Mexico, Hong Kong, Israel, Chile, Peru, Malaysia, Vietnam, Indonesia, Europe, India, Australia, New Zealand, South Africa and South Korea. The patent is now granted in South Africa.

Further provisional patent filings are also expected to be filed to capture and protect additional patentable subject matter that is identified, namely further enhanced formulations, combination treatments, use of recombinant products, modes of action and molecular targets.

Foreign Operations:

As of March 31, 2014, the Company’s operations are based in Australia.

NOTE 10 - DERIVATIVE FINANCIAL INSTRUMENTS and FAIR VALUE MEASUREMENTS

Derivative Financial Instruments:

The Company applies the provisions of ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC Topic 815-40”), under which convertible instruments and warrants, which contain terms that protect holders from declines in the stock price (reset provisions), may not be exempt from derivative accounting treatment. As a result, warrants are recorded as a liability and are revalued at fair value at each reporting date. Further, under derivative accounting, the warrants are recorded at their fair value. If the fair value of the warrants exceeds the face value of the related debt, the excess is recorded as change in fair value in operations on the issuance date. The Company has 3,000,000 warrants with repricing options outstanding at March 31, 2014.

The Company calculates the estimated fair values of the liabilities for warrant derivative instruments at each quarter-end using the BSM option pricing model. The closing price of the Company’s common stock at September 30, 2013 and March 31, 2014 was $0.20 and $0.10, respectively. Volatility, expected term and risk free interest rates used to estimate the fair value of derivative liabilities at March 31, 2014, are indicated in the table that follows. The volatility was based on the comparative companies method since the Company’s stock is very thinly traded, the expected term is equal to the remaining term of the warrants and the risk free rate is based upon rates for treasury securities with the same term.

Warrants

	September 30, 2013			March 31, 2014
Volatility		53	%		53	%
Expected Term		2.25			1.75
Risk Free Interest Rate		0.4	%		0.44	%
Expected dividend yield	none			none

PROPANC HEALTH GROUP CORPORATION AND SUBSIDIARY

(A Development Stage Company)

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

March 31, 2014

Fair Value Measurements:

We currently measure and report at fair value the liability for warrant derivative instruments. The fair value liabilities for price adjustable warrants have been recorded as determined utilizing the BSM option pricing model and Monte Carlo simulations. The following tables summarize our financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2014:

Quoted Prices

Significant

Balance at

in Active

Other

Significant

March 31,

Markets for

Observable

Unobservable

2014

Identical Assets

Inputs

(Level 1)

(Level 2)

(Level 3)

Fair value of liability for warrant derivative instruments

$ 111,343

$ —

$ 111,343

The following is a roll forward for the nine months ended March 31, 2014 of the fair value liability of price adjustable warrant derivative instruments:

	Fair Value of
	Liability for
	Warrant
	Derivative
	Instruments

Balance at June 30, 2013	$	0
Initial fair value recording of warrant derivative liability as debt discount		144,241
Effects of foreign currency exchange rate changes		(5,882)
Change in fair value included in statements of operations		(27,016)
Balance at March 31, 2014	$	111,343

NOTE 11 - SUBSEQUENT EVENTS

In April 2014, the Company received a loan for the sum of $2,774 from the Company’s Chief Executive Officer.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

Special Note Regarding Forward-Looking Statements

The following discussion should be read in conjunction with our unaudited consolidated financial statements, which are included elsewhere in this Quarterly Report on Form 10-Q (this “Report”). Certain statements in this Report concerning our business prospects or future financial performance, anticipated revenues, expenses, profitability or other financial items, estimates as to size, growth in or projected revenues, developments in industry regulations and the application of such regulations, expected outcomes of pending or potential litigation and regulatory actions, and our strategies, plans and objectives, together with other statements that are not historical facts, are "forward-looking statements" as that term is defined under the federal securities laws. In some cases, you can identify forward-looking statements by terminology such as “may,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other comparable terminology. All of these forward-looking statements are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. You should carefully review the risks described herein and in other documents we file from time to time with the Securities and Exchange Commission (“SEC”), including our Final Prospectus on Form 424b filed on December 16, 2011, particularly in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements.

Company Overview

We are a research and development company whose primary activity is to develop new treatments for chronic diseases, in particular cancer. Since inception, substantially all of the efforts of the Company have been the development of new cancer treatments targeting high risk patients who need a follow-up, non-toxic, long-term therapy which prevents the cancer from returning and spreading. The Company is a development stage enterprise and has begun raising capital, financial planning, establishing sources of supply, and acquiring property and equipment. We have generated no revenue, have no cancer treatment products available to market and have no products which have reached the clinical trial stage. We require substantial additional financing to develop our products.

Propanc Pty Ltd was incorporated in Melbourne, Victoria Australia on October 15, 2007. On November 23, 2010, Propanc Health Group Corporation was incorporated in the state of Delaware. In January 2011, Propanc Health Group Corporation acquired all of the outstanding shares of Propanc Pty Ltd on a one-for-one basis making it a wholly-owned subsidiary.

Critical Accounting Estimates

Below the Company will provide a discussion of its more subjective accounting estimation processes for purposes of (i) explaining the methodology used in calculating the estimates, (ii) the inherent uncertainties pertaining to such estimates, and (iii) the possible effects of a significant variance in actual experience, from that of the estimate, on the Company’s financial condition. Estimates are founded upon assumptions that, if incorrect, could have a material adverse impact on the Company’s results of operations and financial condition.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates. Significant estimates in the accompanying unaudited consolidated financial statements include, without limitation, those involving depreciable lives and valuation of property and equipment and intangible assets, allowance for uncollectable receivables, valuation of derrivatives, valuation of benificial conversion feature in convertible debt, valuation of equity based instruments issued for other than cash and the valuation allowance on deferred tax assets and foreign currency translation due to the application of certain average exchange rates in lieu of spot rates on translation dates.

Foreign Currency Translation and Comprehensive Income (Loss)

Research and Development Tax Credits

The Company may apply for research and development tax concessions with the Australian Taxation Office on an annual basis. Although the application amount is possible to estimate at year end, the Australian Taxation Office may reject or materially alter the amount. Accordingly, the Company does not recognize the benefit of the application amount until cash receipt, since collectability is not certain until such time. The tax concession is a refundable credit. If the Company has net income then the Company can receive the credit which reduces its income tax liability. If the Company has net losses then the Company may still receive a cash payment in respect to the credit; provided, however, the Company’s net operating loss carryforwards are reduced by the gross equivalent loss that would produce the credit amount when the income tax rate is applied to that gross amount. The concession is recognized as an income tax benefit, in operations, upon receipt.

Results of Operations for the Three Months Ended March 31, 2014 Compared to the Three Months Ended March 31, 2013

Revenue. For the three month periods ended March 31, 2014 and 2013, we did not generate revenues.

Gross Profit. Since we did not record or achieve any revenues for the three month periods ended March 31, 2014 and 2013, we did not have any costs associated with sales; and therefore we had no gross profits to report.

Operating Expenses. Our total operating expenses were $104,315 for the three months ended March 31, 2014, compared to $229,367 for the same period in 2013. The decrease is mainly related to less expense in 2014 associated with the amortization of prepaid shares issued for services.

Provision for Income Taxes. There was no provision of tax liability for the three month period ending March 31, 2014 due to the Company's historical losses.

Net Earnings (loss). We generated net losses of $66,865 for the three months ended March 31, 2014 compared to approximately $337,672 for the same period in 2013.

Results of Operations for the Nine Months Ended March 31, 2014 Compared to the Nine Months Ended March 31, 2013

Revenue. For the nine month periods ended March 31, 2014 and 2013, we did not generate revenues.

Gross Profit. Since we did not record or achieve any revenues for the nine month periods ended March 31, 2014 and 2013, we did not have any costs associated with sales; and therefore we had no gross profits to report.

Operating Expenses. Our total operating expenses were $638,338 for the nine months ended March 31, 2014, compared to $1,172,127 for the same period in 2013. The decrease is mainly related to less expense in 2014 associated with the amortization of prepaid shares issued for services.

Provision for Income Taxes. There was no provision of tax liability for the period ending March 31, 2014, due to the Company's historical losses, however, we did record an income tax benefit relating to Research and Development tax concessions received of $367,421 since inception.

Net Earnings (Loss). We generated net losses of $611,977 for the nine months ended March 31, 2014, compared to $1,217,990 for the same period in 2013.

Research and Development

In accordance with ASC 730-10, research and development expenditures for the Company's products are expensed when incurred, and are included in operating expenses. The Company recognized research and development costs of $0 and $1,744 for the nine months ended March 31, 2014 and 2013, respectively.

Liquidity and Capital Resources

General . At March 31, 2014 we had a cash balance of $40. We have historically met our cash needs through a combination of proceeds from private placements of our securities and from loans. Our cash requirements are generally for operating activities. We need additional funding to sustain operations and efforts are now underway for additional capital through the sale of registered securities and related party advances. However, there can be no assurance that we will secure the necessary funding or otherwise be able to meet our working capital needs.

Our operating activities used cash in operations of $137,667 for the nine months ended March 31, 2014, and we used cash in operations of $96,701 for the same period in 2013. The principal elements of cash flow from operations for the nine months ended March 31, 2014, included a net loss of $611,977, offset by shares issued for services of $237,833, income from the change in warrant derivative liabilty of $27,016, amortization of debt discounts of $30,434, a decrease in operating working capital elements of approximately $230,000, depreciation expense of $538, and amoratization of stock based prepaid expenses of $6,667.

Cash used in investing activities during the nine months ended March 31, 2014, was $0 and $0 during the same period in 2013.

Cash received in our financing activities was $136,745 for the nine months ended March 31, 2014, compared to cash received of $98,992 during the same period in 2013. The majority of 2014 funding related to the issuance of a convertible promissory note.

The Company estimates that, depending on the progress of its research and development activities, it will require approximately $7,500,000 to adequately fund operating activities and execute its development program in the next twelve to eighteen months. Presently, we do not have enough cash to continue operations for the next twelve months. If we are unable to obtain additional funds on favorable terms or at all, we may be required to delay, reduce the scope of, or eliminate one or more of our research or development programs, or to cease or reduce our operating activities.

Going Concern

As reflected in the accompanying unaudited consolidated financial statements, for the nine months ended March 31, 2014, the Company was in the development stage, had no revenues and had a net loss of $611,977 and net cash used in operations of $137,667. Additionally, as of March 31, 2014, the Company had a negative cash balance and a working capital deficit of $1,165,194, loans in default and a deficit accumulated during development stage of $17,335,330. These conditions raise substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on successful completion of the Company’s development program and, ultimately, the attainment of profitable operations. We can provide no assurance that we will be able to generate a sufficient amount of revenue, if any, from our business in order to achieve profitability. The unaudited consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Off-Balance Sheet Arrangements

As of March 31, 2014, we had no off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

With the participation of our Chief Executive Officer and Chief Accounting Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), as of the end of the period covered by this Report. Based upon such evaluation, our Chief Executive Officer and Chief Financial Officer has concluded that, as of the end of such period, our disclosure controls and procedures were not effective due to the material weakness noted below, in ensuring that (i) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and (ii) information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Material weakness: due to the small size of its staff, the Company did not have sufficient segregation of duties to support its internal control over financial reporting. We plan to rectify this weakness by hiring additional accounting personnel once we have the necessary resources to do so.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal controls over financial reporting during the quarter ended March 31, 2014, that have materially affected, or are reasonable likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS.

None.

ITEM 1A. RISK FACTORS

Not applicable.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

None.

ITEM 5. OTHER INFORMATION.

None.

ITEM 6. EXHIBITS.

Exhibit Number		Description

31.1		Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2		Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act.
32.2		Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act .
101.INS*		XBRL Instance Document (1)
101.SCH*		XBRL Schema Document (1)
101.CAL*		XBRL Calculation Linkbase Document (1)
101.LAB*		XBRL Label Linkbase Document(1)
101.PRE*		XBRL Presentation Linkbase Document (1)
101.DEF*		XBRL Definition Linkbase Document (1)

__________

* Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	PROPANC HEALTH GROUP CORPORATION

Date: May 20, 2014	By:	/s/ James Nathanielsz
	Name:	James Nathanielsz
	Title:	Chief Executive Officer, Chief Financial Officer and Chief Accounting Officer

TABLE OF CONTENTS

Part I Financial Information Item 1. Financial Statements Note 1 Nature Of Operations, Basis Of Presentation and Summary Of Significant Accounting and Reporting Policies Note 2 Going Concern Note 3 Due To Directors - Related Party Note 4 Loans Note 5 Convertible Debenture Note 6 Stockholders Equity (deficit)Note 7 Commitments and Contingencies Note 8 Related Party Transactions Note 9 Concentrations and Risks Note 10 - Derivative Financial Instruments and Fair Value Measurements Note 11 - Subsequent Events Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 3. Quantitative and Qualitative Disclosures About Market Risk Item 4. Controls and Procedures Part II Other Information Item 1. Legal Proceedings Item 1A. Risk Factors Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds Item 3. Defaults Upon Senior Securities Item 4. Mine Safety Disclosures Item 5. Other Information Item 6. Exhibits

Exhibits

31.1 CertificationofChief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 CertificationofChief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification ofChief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act. 32.2 Certification ofChief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act .

PPCB 10-Q Quarter ended March 31, 2014

Exhibits